These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 26522776)

  • 1. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options.
    Burnett JP; Korkaya H; Ouzounova MD; Jiang H; Conley SJ; Newman BW; Sun L; Connarn JN; Chen CS; Zhang N; Wicha MS; Sun D
    Sci Rep; 2015 Nov; 5():15821. PubMed ID: 26522776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
    Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
    Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
    BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-Activation.
    Kanzaki H; Mukhopadhya NK; Cui X; Ramanujan VK; Murali R
    Monoclon Antib Immunodiagn Immunother; 2016 Feb; 35(1):1-11. PubMed ID: 26871511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population.
    Korkaya H; Kim GI; Davis A; Malik F; Henry NL; Ithimakin S; Quraishi AA; Tawakkol N; D'Angelo R; Paulson AK; Chung S; Luther T; Paholak HJ; Liu S; Hassan KA; Zen Q; Clouthier SG; Wicha MS
    Mol Cell; 2012 Aug; 47(4):570-84. PubMed ID: 22819326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
    Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
    Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival.
    Baker A; Wyatt D; Bocchetta M; Li J; Filipovic A; Green A; Peiffer DS; Fuqua S; Miele L; Albain KS; Osipo C
    Oncogene; 2018 Aug; 37(33):4489-4504. PubMed ID: 29743588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
    Chung WP; Huang WL; Liao WA; Huang WL; Liu YY; Su WC
    Cancer Med; 2021 Apr; 10(7):2370-2379. PubMed ID: 33665980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN.
    Aghazadeh S; Yazdanparast R
    Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1970-1980. PubMed ID: 28499822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of PTEN, p53 and EGFR in the molecular subtypes of breast carcinoma and 
the correlation among them].
    Li X; Wang Q; Fu L; Liu M; Yu X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 40(9):973-8. PubMed ID: 26408616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells.
    Mao Y; Zhang Y; Qu Q; Zhao M; Lou Y; Liu J; huang O; Chen X; Wu J; Shen K
    Mol Biosyst; 2015 Apr; 11(4):1029-40. PubMed ID: 25648538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
    Zhao Y; Wang Z; Jiang Y; Yang C
    Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
    Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
    Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EPHA5 mediates trastuzumab resistance in HER2-positive breast cancers through regulating cancer stem cell-like properties.
    Li Y; Chu J; Feng W; Yang M; Zhang Y; Zhang Y; Qin Y; Xu J; Li J; Vasilatos SN; Fu Z; Huang Y; Yin Y
    FASEB J; 2019 Apr; 33(4):4851-4865. PubMed ID: 30620624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.
    Stern HM; Gardner H; Burzykowski T; Elatre W; O'Brien C; Lackner MR; Pestano GA; Santiago A; Villalobos I; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Nuciforo P; Bee V; Mackey J; Slamon DJ; Press MF
    Clin Cancer Res; 2015 May; 21(9):2065-74. PubMed ID: 25649019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.
    Wang C; Bai C; Zhang Z; Zhou H; Gao H; Wang S; Yuan Y
    Cancer Gene Ther; 2024 Oct; 31(10):1525-1535. PubMed ID: 39122832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ITGβ3 to Overcome Trastuzumab Resistance through Epithelial-Mesenchymal Transition Regulation in HER2-Positive Breast Cancer.
    Boz Er AB; Er I
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
    Wang Y; Liu Y; Du Y; Yin W; Lu J
    Curr Med Res Opin; 2013 Jun; 29(6):633-42. PubMed ID: 23574264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.